Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | DIAL me in: dual immunodulation in aggressive lymphoma

Jose Villasboas • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Checkpoint inhibitors Nivolumab Varlilumab
DIAL

Jose Villasboas, MD, Mayo Clinic, Rochester, Minnesota, MN, discusses the rationale and design of the ongoing Phase II Dual Immunomodulation in Aggressive Lymphoma (DIAL) trial (NCT03038672). This trial investigates varilumab plus nivolumab in aggressive B-cell lymphomas. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Jose Villasboas

2:43
Interim analysis of the ELM-2 study: odronextamab in patients with R/R follicular lymphoma
Jose Villasboas • 10 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals